The prolactin family hormones regulate vascular tone through NO and prostacyclin production in isolated rat aortic rings

Acta Pharmacologica Sinica

Volumn 36, Issue 5, 2015, Pages 572-586

  Gonzalez, Carmen ^a   Rosas Hernandez, Hector ^a,c   Jurado Manzano, Brenda ^a   Ramirez Lee, Manuel Alejandro ^a   Salazar Garcia, Samuel ^a   Martinez Cuevas, Pedro Pablo ^a   Velarde Salcedo, Aída Jimena ^a   Morales Loredo, Humberto ^b   Espinosa Tanguma, Ricardo ^b   Ali, Syed F ^c   Rubio, Rafael ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

aortic endothelial cells; aortic rings; endothelium; eNOS; growth hormones; NO; placental lactogen; prolactin; prostaglandins

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PLACENTA LACTOGEN; PROLACTIN; PROLACTIN RECEPTOR; PROSTACYCLIN; SERINE; SODIUM CHLORIDE; HUMAN GROWTH HORMONE; NOS3 PROTEIN, RAT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADULT; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; IN VITRO STUDY; ISOLATED ORGAN; ISOMETRICS; MALE; NONHUMAN; RAT; TENSION; VASCULAR RING; VASODILATATION; WESTERN BLOTTING; ANIMAL; AORTA; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME; VASOCONSTRICTION; WISTAR RAT;

ANIMALS; AORTA; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; EPOPROSTENOL; HUMAN GROWTH HORMONE; IN VITRO TECHNIQUES; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PLACENTAL LACTOGEN; PROLACTIN; RATS, WISTAR; RECEPTORS, SOMATOTROPIN; SERINE; SIGNAL TRANSDUCTION; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 84929172183     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.159     Document Type: Article

References (66)

1. Clapp C, Thebault S, Jeziorski MC, Martinez De La Escalera G. Peptide hormone regulation of angiogenesis. Physiol Rev 2009; 89: 1177-215.
2. Tirapelli CR, Bonaventura D, Tirapelli LF, de Oliveira AM. Mechanisms underlying the vascular actions of endothelin 1, angiotensin II and bradykinin in the rat carotid. Pharmacology 2009; 84: 111-26.
3. Cotton JM, Kearney MT, Shah AM. Nitric oxide and myocardial function in heart failure: friend or foe? Heart 2002; 88: 564-6.
4. Duckles SP, Miller VM. Hormonal modulation of endothelial NO production. Pflugers Arch 2010; 459: 841-51.
5. Do KH, Kim MS, Kim JH, Rhim BY, Lee WS, Kim CD, et al. Angiotensin II-induced aortic ring constriction is mediated by phosphatidylinositol 3-kinase/L-type calcium channel signaling pathway. Exp Mol Med 2009; 41: 569-76.
6. Cairrao E, Alvarez E, Carvas JM, Santos-Silva AJ, Verde T. Non-genomic vasorelaxant effects of 17p-estradiol and progesterone in rat aorta are mediated by L-type Ca2+ current inhibition. Acta Pharmacol Sin 2012; 33: 615-24.
7. Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011; 301: R267-75.
8. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and pheno-types observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-68.
9. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lac-togen family in angiogenesis. J Endocrinol 2002; 173: 219-38.
10. Ho KK, O'Sullivan AJ, Hoffman DM. Metabolic actions of growth hormone in man. Endocr J 1996; 43: S57-63.
11. Lewis UJ. Growth Hormone What is it and what does it do? Trends Endocrinol Metab 1992; 3: 117-21.
12. Nicoll CS, Mayer GL, Russell SM. Structural features of prolactins and growth-hormones that can be related to their biological properties. Endocr Rev 1986; 7: 169-203.
13. Walker WH, Fitzpatrick SL, Barrera-Saldana HA, Resendez-Perez D, Saunders GF. The human placental lactogen genes: structure, function, evolution and transcriptional regulation. Endocr Rev 1991; 12: 316-28.
14. Clapp C, Martinez de la Escalera L, Martinez de la Escalera G. Prolactin and blood vessels: a comparative endocrinology perspective. Gen Comp Endocrinol 2012; 176: 336-40.
15. Grossini E, Molinari C, Battaglia A, Mary DA, Ribichini F, Surico N, et al. Human placental lactogen decreases regional blood flow in anesthetized pigs. J Vasc Res 2006; 43: 205-13.
16. Molinari C, Battaglia A, Bona G, Grossini E, Mary DA, Vacca G. The role of nitric oxide in the coronary vasoconstriction caused by growth hormone in anaesthetized pigs. Exp Physiol 2000; 85: 203-8.
17. Molinari C, Grossini E, Mary DA, Uberti F, Ghigo E, Ribichini F, et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 2007; 148: 4080-90.
18. Bohlooly YM, Carlson L, Olsson B, Gustafsson H, Andersson IJ, Tornell J, et al. Vascular function and blood pressure in GH transgenic mice. Endocrinology 2001; 142: 3317-23.
19. Karmazyn M, Daly MJ, Moffat MP, Dhalla NS. A possible mechanism of inotropic action of prolactin on rat heart. Am J Physiol 1982; 243: E458-63.
20. Manku MS, Nassar BA, Horrobin DF. Effects of prolactin on the responses of rat aortic and arteriolar smooth-muscle preparations to noradrenaline and angiotensin. Lancet 1973; 302: 991-4.
21. Manku MS, Horrobin DF, Karmazyn M, Cunnane SC. Prolactin and zinc effects on rat vascular reactivity: possible relationship to dihomo-gamma-linolenic acid and to prostaglandin synthesis. Endocrinology 1979; 104: 774-9.
22. Nassar BA, Manku MS, Reed JD, Tynan M, Horrobin DF. Actions of prolactin and frusemide on heart rate and rhythm. Br Med J 1974; 2: 27-9.
23. Mills DE, Buckman MT, Peake GT. Effect of prolactin administration and suppression on blood pressure and body fluid compartments in the rat. Endocrinology 1981; 109: 1590-6.
24. Mills DE, Ward RP. Effect of prolactin on blood pressure and cardiovascular responsiveness in the rat. Proc Soc Exp Biol Med 1986; 181: 3-8.
25. Mtabaji JP, Manku MS, Horrobin DF. Vascular actions of furosemide and bumetanide on the rat superior mesenteric vascular bed: interactions with prolactin and prostaglandins. Can J Physiol Pharmacol 1976; 54: 357-66.
26. Thum T, Tsikas D, Frolich JC, Borlak E. Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line. FEBS Lett 2003; 555: 567-71.
27. Boger RH, Skamira C, Bode-Boger SM, Brabant G, von zur Muhlen A, Frolich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 1996; 98: 2706-13.
28. Napoli R, Guardasole V, Angelini V, D'Amico F, Zarra E, Matarazzo M, et al. Acute effects of growth hormone on vascular function in human subjects. J Clin Endocrinol Metab 2003; 88: 2817-20.
29. Li G, Del Rincon JP, Jahn LA, Wu Y, Gaylinn B, Thorner MO, et al. Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I. J Clin Endocrinol Metab 2008; 93: 1379-85.
30. Gola M, Bonadonna S, Doga M, Giustina A. Clinical review: Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab 2005; 90: 1864-70.
31. Capaldo B, Guardasole V, Pardo F, Matarazzo M, Di Rella F, Numis F, et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation 2001; 103: 520-4.
32. Napoli R, Guardasole V, Matarazzo M, Palmieri EA, Oliviero U, Fazio S, et al. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J Am Coll Cardiol 2002; 39: 90-5.
33. McMurtry JP, Wexler BC. Hyperprolactinemia and hyperadrenocorti-cism accompanied by normal blood pressure in Sprague-Dawley rats. Proc Soc Exp Biol Med 1981; 168: 114-8.
34. Nassar BA, Horrobin DF, Tynan M, Manku MS, Davies PA. Seasonal and sexual variations in the responsiveness of rabbit hearts to prolac-tin. Endocrinology 1975; 97: 1008-13.
35. Wessels F, Hoffmann D, Wagner H, Zumkley H. Influence of family history of hypertension on the relationships between blood pressure, body weight, electrolyte metabolism, renin, prolactin and parathor-mone. Clin Sci (Lond) 1981; 61: 359s-62s.
36. Rosas-Hernandez H, Jimenez-Badillo S, Martinez-Cuevas PP, Gracia-Espino E, Terrones H, Terrones M, et al. Effects of 45-nm silver nanoparticles on coronary endothelial cells and isolated rat aortic rings. Toxicol Lett 2009; 191: 305-13.
37. Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J 2002; 16: 1057-63.
38. Engler MB, Engler MM, Browne A, Sun YP, Sievers R. Mechanisms of vasorelaxation induced by eicosapentaenoic acid (20: 5n-3) in WKY rat aorta. Br J Pharmacol 2000; 131: 1793-9.
39. Xue YL, Shi HX, Murad F, Bian K. Vasodilatory effects of cinnamalde-hyde and its mechanism of action in the rat aorta. Vasc Health Risk Manag 2011; 7: 273-80.
40. Gurpinar T, Gok S. Vasodilator effects of cromakalim and HA 1077 in diabetic rat aorta. Swiss Med Wkly 2012; 142: w13558.
41. Gonzalez C, Corbacho AM, Eiserich JP, Garcia C, Lopez-Barrera F, Mo-rales-Tlalpan V, et al. 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothe-lium-dependent vasorelaxation. Endocrinology 2004; 145: 5714-22.
42. Aschner JL, Zeng H, Kaplowitz MR, Zhang Y, Slaughter JC, Fike CD. Heat shock protein 90-eNOS interactions mature with postnatal age in the pulmonary circulation of the piglet. Am J Physiol Lung Cell Mol Physiol 2009; 296: L555-64.
43. de la Rosa AP, Montoya AB, Martinez-Cuevas P, Hernandez-Ledesma B, Leon-Galvan MF, De Leon-Rodrfguez A, et al. Tryptic amaranth glutelin digests induce endothelial nitric oxide production through inhibition of ACE: antihypertensive role of amaranth peptides. Nitric Oxide 2010; 23: 106-11.
44. Garcia C, Aranda J, Arnold E, Thebault S, Macotela Y, Lopez-Casillas F, et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest 2008; 118: 2291-300.
45. Venema VJ, Marrero MB, Venema RC. Bradykinin-stimulated protein tyrosine phosphorylation promotes endothelial nitric oxide synthase translocation to the cytoskeleton. Biochem Biophys Res Commun 1996; 226: 703-10.
46. Bird IM. Endothelial nitric oxide synthase activation and nitric oxide function: new light through old windows. J Endocrinol 2011; 210: 239-41.
47. Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, et al. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 2011; 210: 271-84.
48. Vanhoutte PM. Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly. Hypertension 2011; 57: 526-31.
49. Sausbier M, Schubert R, Voigt V, Hirneiss C, Pfeifer A, Korth M, et al. Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 2000; 87: 825-30.
50. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001; 280: F193-206.
51. Takahashi S, Mendelsohn ME. Synergistic activation of endothelial nitric-oxide synthase (eNOS) by HSP90 and Akt: calcium-independent eNOS activation involves formation of an HSP90-Akt-CaM-bound eNOS complex. J Biol Chem 2003; 278: 30821-7.
52. Walford G, Loscalzo J. Nitric oxide in vascular biology. J Thromb Hae-most 2003; 1: 2112-8.
53. Thum T, Bauersachs J. Growth hormone regulates vascular function -what we know from bench and bedside. Eur J Clin Pharmacol 2006; 62: 29-32.
54. Krause BJ, Hanson MA, Casanello P. Role of nitric oxide in placental vascular development and function. Placenta 2011; 32: 797-805.
55. Wickman A, Friberg P, Adams MA, Matejka GK, Brantsing C, Guron G, et al. Induction of growth hormone receptor and insuline-like growth factor-1 mRNA in aorta and caval vein during hemodynamic challenge. Hypertension 1997; 29: 123-30.
56. Kawabe J, Ushikubi F, Hasebe N. Prostacyclin in vascular diseases. Recent insights and future perspectives. Circ J 2010; 74: 836-43.
57. Blanco-Rivero J, Cachofeiro V, Lahera V, Aras-Lopez R, Marquez-Rodas I, Salaices M, et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension 2005; 46: 107-12.
58. Ricken AM, Traenkner A, Merkwitz C, Hummitzsch K, Grosche J, Spanel-Borowski K. The short prolactin receptor predominates in endothelial cells of micro-and macrovascular origin. J Vasc Res 2007; 44: 19-30.
59. Chiwororo WD, Ojewole JA. Biphasic effect of Psidium guajava Linn. (Myrtaceae) leaf aqueous extract on rat isolated vascular smooth muscles. J Smooth Muscle Res 2008; 44: 217-29.
60. Wong ES, Man RY, Vanhoutte PM, Ng KF. Dexmedetomidine induces both relaxations and contractions, via different {alpha}2-adrenoceptor subtypes, in the isolated mesenteric artery and aorta of the rat. J Pharmacol Exp Ther 2010; 335: 659-64.
61. Castillo-Hernandez J, Torres-Tirado D, Barajas-Espinosa A, Chi-Ahumada E, Ramiro-Dfaz J, Ceballos G, et al. Two dissimilar AT1 agonists distinctively activate AT1 receptors located on the luminal membrane of coronary endothelium. Vascul Pharmacol 2009; 51: 314-22.
62. Ishihata A, Endoh M. Species-related differences in inotropic effects of angiotensin II in mammalian ventricular muscle: receptors, subtypes and phosphoinositide hydrolysis. Br J Pharmacol 1995; 114: 447-53.
63. Koch-Weser J. Nature of the inotropic action of angiotensin on ventricular myocardium. Circ Res 1965; 16: 230-7.
64. Drake MT, Shenoy SK, Lefkowitz RJ. Trafficking of G protein-coupled receptors. Circ Res 2006; 99: 570-82.
65. Firdolas F, Ogras MS, Ozan T, Onur R, Orhan I. In vitro examination of effects of hyperprolactinemia and hypoprolactinemia on seminal vesicle contraction. Urology 2013; 81: 557-61.
66. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, Lykka M, Kyrkou K, Rizos D, et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 2009; 54: 98-105.